Astec LifeSciences Balance Sheet Health
Financial Health criteria checks 1/6
Astec LifeSciences has a total shareholder equity of ₹2.9B and total debt of ₹5.0B, which brings its debt-to-equity ratio to 171.5%. Its total assets and total liabilities are ₹8.8B and ₹5.9B respectively.
Key information
171.5%
Debt to equity ratio
₹5.00b
Debt
| Interest coverage ratio | n/a |
| Cash | ₹20.68m |
| Equity | ₹2.92b |
| Total liabilities | ₹5.90b |
| Total assets | ₹8.82b |
Recent financial health updates
Here's Why Astec LifeSciences (NSE:ASTEC) Can Manage Its Debt Responsibly
Jun 28
Is Astec LifeSciences (NSE:ASTEC) A Risky Investment?
Dec 13Does Astec LifeSciences (NSE:ASTEC) Have A Healthy Balance Sheet?
May 02Recent updates
Shareholders May Be Wary Of Increasing Astec LifeSciences Limited's (NSE:ASTEC) CEO Compensation Package
Jul 23Market Participants Recognise Astec LifeSciences Limited's (NSE:ASTEC) Revenues Pushing Shares 28% Higher
Jul 03Astec LifeSciences Limited (NSE:ASTEC) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable
Mar 15Astec LifeSciences (NSE:ASTEC) Could Be Struggling To Allocate Capital
May 17Shareholders Are Optimistic That Astec LifeSciences (NSE:ASTEC) Will Multiply In Value
Oct 14We Ran A Stock Scan For Earnings Growth And Astec LifeSciences (NSE:ASTEC) Passed With Ease
Jul 27Here's Why Astec LifeSciences (NSE:ASTEC) Can Manage Its Debt Responsibly
Jun 28A Look At The Intrinsic Value Of Astec LifeSciences Limited (NSE:ASTEC)
Jun 03Analysts Just Published A Bright New Outlook For Astec LifeSciences Limited's (NSE:ASTEC)
May 08Astec LifeSciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
May 06Why We Like The Returns At Astec LifeSciences (NSE:ASTEC)
Jan 25Is Astec LifeSciences (NSE:ASTEC) A Risky Investment?
Dec 13We Take A Look At Why Astec LifeSciences Limited's (NSE:ASTEC) CEO Has Earned Their Pay Packet
Jul 21Does Astec LifeSciences (NSE:ASTEC) Have A Healthy Balance Sheet?
May 02The Trend Of High Returns At Astec LifeSciences (NSE:ASTEC) Has Us Very Interested
Apr 17Do Astec LifeSciences's (NSE:ASTEC) Earnings Warrant Your Attention?
Apr 02Is Astec LifeSciences Limited's (NSE:ASTEC) Shareholder Ownership Skewed Towards Insiders?
Mar 18Have Insiders Been Selling Astec LifeSciences Limited (NSE:ASTEC) Shares?
Mar 05Did You Miss Astec LifeSciences' (NSE:ASTEC) Whopping 481% Share Price Gain?
Feb 20A Look At Astec LifeSciences' (NSE:ASTEC) CEO Remuneration
Feb 08Declining Stock and Solid Fundamentals: Is The Market Wrong About Astec LifeSciences Limited (NSE:ASTEC)?
Jan 28What Does Astec LifeSciences Limited's (NSE:ASTEC) Share Price Indicate?
Jan 17
Why We Like The Returns At Astec LifeSciences (NSE:ASTEC)
Jan 08I Ran A Stock Scan For Earnings Growth And Astec LifeSciences (NSE:ASTEC) Passed With Ease
Dec 28Is Astec LifeSciences Limited (NSE:ASTEC) Popular Amongst Insiders?
Dec 18Financial Position Analysis
Short Term Liabilities: ASTEC's short term assets (₹3.0B) do not cover its short term liabilities (₹3.7B).
Long Term Liabilities: ASTEC's short term assets (₹3.0B) exceed its long term liabilities (₹2.2B).
Debt to Equity History and Analysis
Debt Level: ASTEC's net debt to equity ratio (170.8%) is considered high.
Reducing Debt: ASTEC's debt to equity ratio has increased from 102.5% to 171.5% over the past 5 years.
Debt Coverage: ASTEC's debt is not well covered by operating cash flow (2.4%).
Interest Coverage: Insufficient data to determine if ASTEC's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 22:16 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Astec LifeSciences Limited is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Asian Markets Securities Private Limited |
| Ankur Periwal | Axis Capital Limited |
| Satish Kumar | CGS International |